PRNewsWire
22 Jul 2026, 11:45 UTC · 10w ago
Verdict
Headline takes no side. We score VBIO +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 89% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Ukraine's Ministry of Health has accepted Valion Bio's Entolimod regulatory dossier for formal review under the Regulatory Equivalence Pathway.
More positive than 94% of claims this week
The technical review for Entolimod in Ukraine could be completed in as little as 45 to 60 days.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 80% of claims this week
Valion Bio has demonstrated a 200-fold manufacturing scale-up via Velocity Bioworks, capable of producing approximately 1.3 million human doses.
More positive than 67% of claims this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The company reached a significant milestone as Ukraine's Ministry of Health accepted its Entolimod dossier for formal regulatory review.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Accesswire
3h ago
−59.3%
Price is moving against the score
$3.17 vs $7.78 close before publication (Jul 21) · not market-adjusted
VBIO chart →
